The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.

Ming YiJing ZhangAnping LiMengke NiuYongxiang YanYing JiaoSuxia LuoPengfei ZhouKongming Wu

Published in: Journal of hematology & oncology (2021)

Our results demonstrated that YM101 could simultaneously block TGF-β and PD-L1 pathways and had a superior anti-tumor effect compared to the monotherapies.

Keyphrases

transforming growth factor
poor prognosis
cancer therapy
epithelial mesenchymal transition
long non coding rna
drug delivery